DURHAM, N.C., Sept. 4, 2024 /PRNewswire/ — EpiCypher®, a trailblazer in epigenetic research technologies, is pleased to announce an exclusive licensing agreement with Fred Hutch Cancer Center. This agreement grants EpiCypher access to pivotal intellectual […]
